BioCentury | Jul 6, 2018
Emerging Company Profile

Tethering bleeding risk

...risk of bleeding. Chairman and CEO Scott Rollins said while antithrombotic drugs including generic heparin, warfarin...
BioCentury | Sep 1, 2017
Clinical News

Eliquis lowers stroke, major bleeding in older non-valvular AF patients

...the risk of stroke and systemic embolism, and the risk of major bleeding, compared to warfarin...
...receiving Eliquis or warfarin in an insurance claims database from Humana Inc. (NYSE:HUM). Compared to warfarin...
...to warfarin. Median follow-up was 6.3 months in Eliquis-treated patients and 8.3 months in the warfarin...
BioCentury | Aug 30, 2017
Clinical News

Eliquis lowers stroke, major bleeding in older NVAF patients

...the risk of stroke and systemic embolism, and the risk of major bleeding, compared to warfarin...
...receiving Eliquis or warfarin in an insurance claims database from Humana Inc. (NYSE:HUM). Compared to warfarin...
...to warfarin. Median follow-up was 6.3 months in Eliquis-treated patients, and 8.3 months in the warfarin...
BioCentury | Jun 20, 2017
Distillery Techniques

Drug properties

...that is rapidly cleared from the circulation. In mice pretreated with an azide analog of warfarin...
...drugs, nanoparticles or metabolites (see "Clearing Chemistry." BioCentury Innovations (June 15, 2017)). The generic anticoagulant warfarin...
...IGBMC), Illkirch, France email: krezel@igbmc.fr CONTACT: Alain Wagner, University of Strasbourg, llkirch-Graffenstaden, France email: alwag@unistra.fr Karen Tkach warfarin Institute...
BioCentury | Jun 15, 2017
Tools & Techniques

Clearing chemistry

...bioorthogonal reaction -- described as "click and clear" -- to neutralize a modified version of warfarin...
...prothrombin time, suggesting the reaction had successfully neutralized the warfarin analog. When mice received the warfarin...
...vivo strategy to counteract post-administration anticoagulant activity of azido-warfarin." Nature Communications (2017) Karen Tkach Tuzman, Senior Writer warfarin BlinkBio...
BioCentury | Jun 14, 2017
Financial News

GenMark raises $75M in upsized follow-on

...gained $0.38 to $12.20 on Friday. GenMark markets panel tests for cystic fibrosis (CF) genotyping, warfarin...
BioCentury | Nov 30, 2016
Clinical News

Pradaxa: Completed Ph III enrollment

...mg oral Pradaxa twice daily plus clopidogrel or Brilinta ticagrelor vs. triple antithrombotic therapy comprising warfarin...
BioCentury | Nov 18, 2016
Clinical News

Xarelto: Ph IIIb PIONEER AF-PCI data

...the primary endpoint of reducing the rate of clinically significant bleeding at 1 year vs. warfarin...
...for both). The rates of MACE were similar between the once- and twice-daily Xarelto and warfarin...
...the once- and twice-daily Xarelto arms both significantly reduced the rate of re-hospitalization vs. the warfarin...
BioCentury | Sep 29, 2016
Product R&D

Safety Factor

...parceling out the thrombosis market across different product classes, with the dietary issues that precipitated warfarin's...
...not succeeded in their Phase III trials," said Mikita. "There were increases in efficacy over warfarin...
BioCentury | Sep 12, 2016
Clinical News

Savaysa: Phase IIIb data

...in 0.5% of patients vs. 1% of patients receiving standard of care (SOC) enoxaparin plus warfarin...
Items per page:
1 - 10 of 292